Business UpdateApr 14, 2026, 12:50 PM
Pelthos Therapeutics Highlights Product Portfolio & Growth Strategy
AI Summary
Pelthos Therapeutics Inc. presented its corporate overview, highlighting its commercial biopharmaceutical focus on growing cutaneous infections products. The company emphasized its synergistic product acquisitions, including Xepi (launched July 2025) and Xeglyze (expected late 2026 launch), leveraging existing commercial infrastructure. Pelthos also noted strong potential revenue streams and a disciplined acquisition model, with a third product targeting 6-12 million U.S. cases annually slated for a first-half 2027 launch.
Key Highlights
- Xepi launched July 2025 with a wholesale acquisition cost (WAC) of $2,008.50.
- Xeglyze expected to launch in late 2026.
- Third product targeting 6-12 million U.S. cases annually, expected launch H1 2027.
- Company stock price was $24.00 with 8.9 million shares outstanding as of March 16, 2026.
Price Impact
More from PTHS